scholarly journals Developing a Brief Neuropsychological Battery for Early Diagnosis of Cognitive Impairment

2019 ◽  
Vol 20 (8) ◽  
pp. 1054.e11-1054.e20 ◽  
Author(s):  
Tau Ming Liew
Keyword(s):  
Cognitive Impairment ◽  
Early Diagnosis ◽  
Neuropsychological Battery

scholarly journals Implications for Early Diagnosis and Treatment in Schizophrenia Due to Correlation between Auditory Perceptual Deficits and Cognitive Impairment

2021 ◽  
Vol 10 (19) ◽  
pp. 4557
Author(s):  
Nikolaos Moschopoulos ◽  
Ioannis Nimatoudis ◽  
Stergios Kaprinis ◽  
Kosmas Boutsikos ◽  
Christos Sidiras ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Early Diagnosis ◽  
Auditory Processing ◽  
Neuropsychological Test ◽  
Thought Disorder ◽  
Auditory Processing Disorder ◽  
Formal Thought Disorder ◽  
Neuropsychological Battery ◽  
Nonpharmacological Treatment ◽  
Experimental Group

It is indicated that auditory perception deficits are present in schizophrenia and related to formal thought disorder. The purpose of the present study was to investigate the association of auditory deficits with cognitive impairment in schizophrenia. An experimental group of 50 schizophrenia patients completed a battery of auditory processing evaluation and a neuropsychological battery of tests. Correlations between neuropsychological battery scores and auditory processing scores were examined. Cognitive impairment was correlated with auditory processing deficits in schizophrenia patients. All neuropsychological test scores were significantly correlated with at least one auditory processing test score. Our findings support the coexistence of auditory processing disorder, severe cognitive impairment, and formal thought disorder in a subgroup of schizophrenia patients. This may have important implications in schizophrenia research, as well as in early diagnosis and nonpharmacological treatment of the disorder.

scholarly journals Reliable Measurements of theβ-Amyloid Pool in Blood Could Help in the Early Diagnosis of AD

2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Pedro Pesini ◽  
Virginia Pérez-Grijalba ◽  
Inmaculada Monleón ◽  
Mercè Boada ◽  
Lluís Tárraga ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Early Diagnosis ◽  
Small Proportion ◽  
Blood Cells ◽  
Plasma Proteins ◽  
Blood Samples ◽  
Striking Result ◽  
Healthy Control ◽  
Amnesic Mild Cognitive Impairment

The present study was aimed at assessing the capability of Aβ1-40 and Aβ1-42 levels in undiluted plasma (UP), diluted plasma (DP), and cell bound (CB) to distinguish between early stages of Alzheimer's disease (AD), amnesic mild cognitive impairment (MCI), and healthy control (HC). Four blood samples from each participant were collected during one month and the levels of Aβ1-40 and Aβ1-42 were determined by a blinded proprietary ELISA sandwich (Araclon Biotech. Zaragoza, Spain). First striking result was that the amount of Aβ1-40 and Aβ1-42 in UP represented only a small proportion (~15%) of the total beta-amyloid pool in blood (βAPB) described here as the sum of Aβ1-40 and Aβ1-42 in blood where they are free in plasma, bound to plasma proteins, and bound to blood cells. Furthermore, we found that levels of Aβ1-40 and Aβ1-42 in UP, DP, and CB were significantly higher in MCI when compared to HC. On average, the totalβAPB was 1.8 times higher in MCI than in HC (P=0.03) and allowed to discriminate between MCI and HC with a sensitivity and specificity over 80%. Thus, quantification of several markers of theβAPB could be useful and reliable in the discrimination between MCI and HC.

scholarly journals Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin

2017 ◽  
Vol 8 (1) ◽  
pp. 131-138 ◽  
Author(s):  
Eva Carro ◽  
Fernando Bartolomé ◽  
Félix Bermejo‐Pareja ◽  
Alberto Villarejo‐Galende ◽  
José Antonio Molina ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Early Diagnosis

scholarly journals Quantitative MRI of Perivascular Spaces at 3T for Early Diagnosis of Mild Cognitive Impairment

2018 ◽  
Vol 39 (9) ◽  
pp. 1622-1628 ◽  
Author(s):  
M. Niazi ◽  
M. Karaman ◽  
S. Das ◽  
X.J. Zhou ◽  
P. Yushkevich ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Early Diagnosis ◽  
Quantitative Mri ◽  
Perivascular Spaces

The problem of cognitive impairment in neurological practice (reference review)

2014 ◽  
Vol 18 (4 (72)) ◽  
Author(s):  
T. I. Purdenko
Keyword(s):  
Cognitive Impairment ◽  
Early Diagnosis ◽  
Neurodegenerative Diseases ◽  
Old Age ◽  
Cognitive Disorders ◽  
Cerebral Diseases ◽  
Success Of Treatment ◽  
The Brain

The article presents an analysis of the literature on the problem of cognitive disorders. It is in old age, when vascular and neurodegenerative diseases of the brain are most frequently diagnosed, leading to cognitive disorders of varying severity: from mild to severe. Early diagnosis of cerebral diseases increases significantly the chances of success of treatment to the problem.

scholarly journals A Deep Learning approach for Diagnosis of Mild Cognitive Impairment Based on MRI Images

2019 ◽  
Vol 9 (9) ◽  
pp. 217 ◽  
Author(s):  
Gorji ◽  
Kaabouch
Keyword(s):  
Deep Learning ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Early Diagnosis ◽  
Brain Structure ◽  
Neurodegenerative Disorder ◽  
Healthy People ◽  
Learning Approach ◽  
Brain Structure And Function ◽  
Percent Accuracy

Mild cognitive impairment (MCI) is an intermediary stage condition between healthy people and Alzheimer’s disease (AD) patients and other dementias. AD is a progressive and irreversible neurodegenerative disorder, which is a significant threat to people, age 65 and older. Although MCI does not always lead to AD, an early diagnosis at the stage of MCI can be very helpful in identifying people who are at risk of AD. Moreover, the early diagnosis of MCI can lead to more effective treatment, or at least, significantly delay the disease’s progress, and can lead to social and financial benefits. Magnetic resonance imaging (MRI), which has become a significant tool for the diagnosis of MCI and AD, can provide neuropsychological data for analyzing the variance in brain structure and function. MCI is divided into early and late MCI (EMCI and LMCI) and sadly, there is no clear differentiation between the brain structure of healthy people and MCI patients, especially in the EMCI stage. This paper aims to use a deep learning approach, which is one of the most powerful branches of machine learning, to discriminate between healthy people and the two types of MCI groups based on MRI results. The convolutional neural network (CNN) with an efficient architecture was used to extract high-quality features from MRIs to classify people into healthy, EMCI, or LMCI groups. The MRIs of 600 individuals used in this study included 200 control normal (CN) people, 200 EMCI patients, and 200 LMCI patients. This study randomly selected 70 percent of the data to train our model and 30 percent for the test set. The results showed the best overall classification between CN and LMCI groups in the sagittal view with an accuracy of 94.54 percent. In addition, 93.96 percent and 93.00 percent accuracy were reached for the pairs of EMCI/LMCI and CN/EMCI, respectively.

Tracking Cognitive Decline in Amnestic Mild Cognitive Impairment and Early-Stage Alzheimer Dementia: Mini-Mental State Examination versus Neuropsychological Battery

2017 ◽  
Vol 44 (1-2) ◽  
pp. 105-117 ◽  
Author(s):  
Joonho Kim ◽  
Han Kyu Na ◽  
Justin Byun ◽  
Jiwon Shin ◽  
Sungsoo Kim ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Disease Progression ◽  
Mental State ◽  
Test Scores ◽  
Mini Mental State Examination ◽  
Magnetic Resonance Images ◽  
Amnestic Mild Cognitive Impairment ◽  
Neuropsychological Battery ◽  
State Examination

Background/Aims: Although the Mini-Mental State Examination (MMSE), Clinical Dementia Rating-Sum of Boxes (CDR-SOB), and neuropsychological batteries are widely used for evaluating cognitive function, it remains elusive which instrument best reflects the longitudinal disease progression in amnestic mild cognitive impairment (aMCI) and probable Alzheimer disease (AD). We investigated whether changes in these three instruments over time correlate with loss of cortical gray matter volume (cGMV). Methods: We retrospectively investigated 204 patients (aMCI, n = 114; AD, n = 90) who had undergone MMSE, CDR-SOB, the dementia version of the Seoul Neuropsychological Screening Battery (SNSB-D), and 3-dimensional T1-weighted magnetic resonance images at least twice. We investigated the partial correlation between annual decline in test scores and percent change of cGMV. Results: In aMCI patients, changes in the SNSB-D total score (r = 0.340, p < 0.001) and CDR-SOB (r = 0.222, p = 0.020), but not MMSE, showed a correlation with cGMV loss, with the SNSB-D total score showing the strongest correlation. In AD patients, decline in all three test scores correlated significantly with cGMV loss, with MMSE exhibiting the strongest correlation (r = 0.464, p < 0.001). Conclusion: In aMCI patients, neuropsychological battery, though time-consuming, was the most adequate tool in tracking disease progression. In AD patients, however, MMSE may be the most effective longitudinal monitoring tool when considering cost-effectiveness.

Using Subtests of the Brain Age Quotient to Screen for Cognitive Deficits among Substance Abusers

1992 ◽  
Vol 75 (1) ◽  
pp. 244-246 ◽  
Author(s):  
William Fals-Stewart
Keyword(s):  
Cognitive Impairment ◽  
Cognitive Deficits ◽  
Substance Abusers ◽  
Attractive Alternative ◽  
Neuropsychological Battery ◽  
T Score ◽  
And Gender ◽  
Screening Device ◽  
Brain Age ◽  
The Brain

The subtests of the Brain Age Quotient, a brief neuropsychological battery, were used to screen for cognitive impairment in a sample of 112 substance abusers. Each of the subtests was scored, using newly developed T scores corrected for age, education, and gender, for which a mean battery score of T < 40 indicates general cognitive impairment. The chance-corrected agreement in finding cognitive dysfunction between this battery and the Average Impairment Rating T score from the Halstead-Reitan battery was adequate, κ = .81. This result suggests that, for discerning global cognitive impairment, this relatively brief neurodiagnostic screening device may be an attractive alternative to the more time-consuming Halstead-Reitan battery.

Sign in / Sign up

Export Citation Format

Share Document